To the best of our knowledge, there are no prospective studies evaluating the efficacy of ICIs plus chemotherapy in driver–oncogene-positive NSCLC other than EGFR mutation and ALK fusion. This evidence concerns the gene EGFR and non-small cell lung carcinoma.